肠道微生物组对淋巴瘤治疗的影响：当前证据与未来治疗方向

The heterogeneity of lymphoma responses to various treatments remains a significant challenge in clinical practice. Emerging evidence implicates the potential role of the gut microbiome in lymphoma pathogenesis and progression. Advances in high-throughput sequencing and metabolomics have significantly enhanced our understanding of the complex interaction between the gut microbiome and lymphoma.

Although causality requires further elucidation, the gut microbiome critically shapes host responses to traditional combined chemotherapy, hematopoietic stem cell transplantation, and targeted therapies, including chimeric antigen receptor T-cell therapy.

Notably, the use of antibiotics, particularly broad-spectrum antibiotics, can alter the gut microbiome, thereby impacting treatment efficacy. Prudent antibiotic management should balance infection control with microbiome-dependent immune homeostasis. Strategies to restore gut microbial balance through a high-fiber diet, probiotics, prebiotics, fecal microbiota transplantation, and butyrate supplementation are critically important. Integrating microbiome-based therapies into lymphoma treatment could establish low-toxicity therapeutic paradigms for lymphoma patients. How gut bacteria affect lymphoma treatment: what we know and future possibilities Lymphoma treatments often work differently for each patient, and scientists now believe the community of bacteria in our gut may help explain these variations.

Research shows these bacteria influence common lymphoma therapies like chemotherapy, stem cell transplants, and CAR-T cell treatment. Problems arise when antibiotics disrupt this delicate bacterial balance, possibly reducing treatment effectiveness. Doctors are now exploring ways to protect helpful gut bacteria while preventing infections.

New approaches include special diets, probiotic supplements, and even microbiota transplants that may boost treatment success. These discoveries could lead to more personalized lymphoma therapies with better results and fewer side effects, offering new hope for lymphoma patients.